These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 26974375)
61. Compensatory changes in the hippocampus of somatostatin knockout mice: upregulation of somatostatin receptor 2 and its function in the control of bursting activity and synaptic transmission. Cammalleri M; Cervia D; Dal Monte M; Martini D; Langenegger D; Fehlmann D; Feuerbach D; Pavan B; Hoyer D; Bagnoli P Eur J Neurosci; 2006 May; 23(9):2404-22. PubMed ID: 16706848 [TBL] [Abstract][Full Text] [Related]
62. Synthesis, in vitro α-glucosidase inhibitory activity and docking studies of novel chromone-isatin derivatives. Wang G; Chen M; Qiu J; Xie Z; Cao A Bioorg Med Chem Lett; 2018 Jan; 28(2):113-116. PubMed ID: 29208524 [TBL] [Abstract][Full Text] [Related]
63. Identification of the Binding Site of Chroman-4-one-Based Sirtuin 2-Selective Inhibitors using Photoaffinity Labeling in Combination with Tandem Mass Spectrometry. Seifert T; Malo M; Lengqvist J; Sihlbom C; Jarho EM; Luthman K J Med Chem; 2016 Dec; 59(23):10794-10799. PubMed ID: 27933951 [TBL] [Abstract][Full Text] [Related]
64. Receptor signaling and endocytosis are differentially regulated by somatostatin analogs. Liu Q; Cescato R; Dewi DA; Rivier J; Reubi JC; Schonbrunn A Mol Pharmacol; 2005 Jul; 68(1):90-101. PubMed ID: 15855408 [TBL] [Abstract][Full Text] [Related]
65. Identification of novel bivalent mimetics of annonaceous acetogenins via a scaffold-hopping strategy. Liu Y; Liu Y; Li Z; Zhou GB; Yao ZJ; Jiang S Bioorg Med Chem Lett; 2014 Apr; 24(7):1650-3. PubMed ID: 24650643 [TBL] [Abstract][Full Text] [Related]
66. Quantitative Structure-Cytotoxicity Relationship of Furo[2,3- Uesawa Y; Sakagami H; Shi H; Hirose M; Takao K; Sugita Y Anticancer Res; 2018 Jun; 38(6):3283-3290. PubMed ID: 29848675 [TBL] [Abstract][Full Text] [Related]
67. Somatostatin inhibits glutamate release from mouse cerebrocortical nerve endings through presynaptic sst2 receptors linked to the adenylyl cyclase-protein kinase A pathway. Grilli M; Raiteri L; Pittaluga A Neuropharmacology; 2004 Mar; 46(3):388-96. PubMed ID: 14975694 [TBL] [Abstract][Full Text] [Related]
68. Synthesis of 3,3'-carbonyl-bis(chromones) and their activity as mammalian alkaline phosphatase inhibitors. Miliutina M; Ejaz SA; Iaroshenko VO; Villinger A; Iqbal J; Langer P Org Biomol Chem; 2016 Jan; 14(2):495-502. PubMed ID: 26490672 [TBL] [Abstract][Full Text] [Related]
69. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. Bertherat J; Tenenbaum F; Perlemoine K; Videau C; Alberini JL; Richard B; Dousset B; Bertagna X; Epelbaum J J Clin Endocrinol Metab; 2003 Nov; 88(11):5353-60. PubMed ID: 14602773 [TBL] [Abstract][Full Text] [Related]
70. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. Lewis I; Bauer W; Albert R; Chandramouli N; Pless J; Weckbecker G; Bruns C J Med Chem; 2003 Jun; 46(12):2334-44. PubMed ID: 12773038 [TBL] [Abstract][Full Text] [Related]
71. Spiro[1H-indene-1,4'-piperidine] derivatives as potent and selective non-peptide human somatostatin receptor subtype 2 (sst2) agonists. Yang L; Guo L; Pasternak A; Mosley R; Rohrer S; Birzin E; Foor F; Cheng K; Schaeffer J; Patchett AA J Med Chem; 1998 Jun; 41(13):2175-9. PubMed ID: 9632348 [No Abstract] [Full Text] [Related]
72. A structure-based approach to understanding somatostatin receptor-4 agonism (sst4). Liu Z; Crider AM; Ansbro D; Hayes C; Kontoyianni M J Chem Inf Model; 2012 Jan; 52(1):171-86. PubMed ID: 22148589 [TBL] [Abstract][Full Text] [Related]
73. Recent advances of chroman-4-one derivatives: synthetic approaches and bioactivities. Emami S; Ghanbarimasir Z Eur J Med Chem; 2015 Mar; 93():539-63. PubMed ID: 25743215 [TBL] [Abstract][Full Text] [Related]
74. New generation dopaminergic agents. 1. Discovery of a novel scaffold which embraces the D2 agonist pharmacophore. Structure-activity relationships of a series of 2-(aminomethyl)chromans. Mewshaw RE; Kavanagh J; Stack G; Marquis KL; Shi X; Kagan MZ; Webb MB; Katz AH; Park A; Kang YH; Abou-Gharbia M; Scerni R; Wasik T; Cortes-Burgos L; Spangler T; Brennan JA; Piesla M; Mazandarani H; Cockett MI; Ochalski R; Coupet J; Andree TH J Med Chem; 1997 Dec; 40(26):4235-56. PubMed ID: 9435894 [TBL] [Abstract][Full Text] [Related]
75. In search for new chemical entities as adenosine receptor ligands: development of agents based on benzo-γ-pyrone skeleton. Gaspar A; Reis J; Matos MJ; Uriarte E; Borges F Eur J Med Chem; 2012 Aug; 54():914-8. PubMed ID: 22703703 [TBL] [Abstract][Full Text] [Related]
79. Chromones as a privileged scaffold in drug discovery: a review. Keri RS; Budagumpi S; Pai RK; Balakrishna RG Eur J Med Chem; 2014 May; 78():340-74. PubMed ID: 24691058 [TBL] [Abstract][Full Text] [Related]
80. Functional characterisation of the putative somatostatin sst2 receptor antagonist CYN 154806. Nunn C; Schoeffter P; Langenegger D; Hoyer D Naunyn Schmiedebergs Arch Pharmacol; 2003 Jan; 367(1):1-9. PubMed ID: 12616335 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]